HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Cryptosporidiosis in newborn calves in Ankara region: clinical, haematological findings and treatment with Lasalocid-NA].

Abstract
In the first part of the present study, a total of 109 faeces samples collected from calves suffering from diarrhoea were examined for Cryptosporidium parvum oocytes and 39 (35.8%) of them were found to be positive. On the basis of oocyte counts, 14 (36%) samples were assessed as mildly infected and 25 (64%) samples as heavily infected. The occurrence of the disease was more common in winter (56.4%) than during other seasons (autuma 0%, summer 15.4% spring 28.2%. In the present study, the ionophore polyetherantibiotic Lasalocid-Na, that is licensed as a feed additive (Bovatec, 15% Lasalocid-Na, Roche AG) in Turkey, was administered to 11 calves naturally infected with Cryptosporidium and its therapeutic effect was evaluated. Lasalocid-Na (8 mg/ kg BW) was given once daily for 3 days added to the milk. The clinical parameters of infected calves were evaluated before and 3 days after the treatment in 24 hour intervals. The oocyst counts of faeces of calves with cryptosporidiosis were between 15 x 10(6) and 96 x 10(6)/mL before treatment. No oocystes were found in faecal samples of 3 calves (27.3%) after 48 hours and 4 (40%) calves after 72 hours of treatment, respectively. The number of oocytes in the faeces of the remaining calves varied between 90 and 1.2 x 10(6)/mL during the respective period. The number of oocystes before treatment was significantly higher than the number of oocytes after treatment. One of the calves died 56 h after the first treatment despite the treatment. The pH of venous blood was decreased prior to treatment as expected. The lowest pH was 6.83, the lowest bicarbonate concentration was 3.80 mmol/l and the lowest base excess was -31.2 mmol/l. After the treatment, pH, pCO2, HCO3- and BE values of the venous blood increased significantly and reached physiological values before discharge. The differences between the values assessed before the treatment and at the 2nd, 3rd, and 4th sampling time were statistically significant. Number of leucocyte and haemoglobin concentration before the treatment were significantly higher than the values after treatment (p < 0.01). These values returned back to physiological ranges 72 hours after first treatment. Lasalocid-Na was rather well tolerated. Side effects such as the decline of the suckling reflex and intoxication symptoms in respect to present administration form and dosage were found only in one calf (9%). Treatment procedure in the present study with Lasalocid-Na was found to be suitable in combination with an adequate infusion therapy for the treatment of calves on farms with problems related to cryptosporidiosis. Although the use of Lasolacid-Na for the treatment of Cryptosporidium infection in the EU is banned, it might be used as an alternative drug outside of the EU since it has a successful effect for preventing reinfections.
AuthorsM Sahal, Z Karaer, S Yasa Duru, S Cizmeci, B Tanyel
JournalDTW. Deutsche tierarztliche Wochenschrift (Dtsch Tierarztl Wochenschr) Vol. 112 Issue 6 Pg. 203-8, 210 (Jun 2005) ISSN: 0341-6593 [Print] Germany
Vernacular TitleCryptosporidien-lnfektionen bei neugeborenen Kälbern aus der Umgebung von Ankara: klinische und hämatologische Untersuchungen sowie Ergebnisse der Behandlung mit Lasalocid-Na.
PMID16028484 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Coccidiostats
  • Ionophores
  • Lasalocid
Topics
  • Animals
  • Animals, Newborn
  • Cattle
  • Cattle Diseases (blood, drug therapy, epidemiology)
  • Coccidiostats (therapeutic use)
  • Cryptosporidiosis (blood, drug therapy, epidemiology, veterinary)
  • Cryptosporidium parvum (isolation & purification)
  • Feces (parasitology)
  • Ionophores (therapeutic use)
  • Lasalocid (therapeutic use)
  • Oocysts (isolation & purification)
  • Seasons
  • Treatment Outcome
  • Turkey (epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: